Li-Fraumeni syndrome: genes and variants
Explore variant evidence for Li-Fraumeni syndrome across 2 analyzed proteins (TP53, CHEK2). Linked ClinVar records include 188 pathogenic or likely pathogenic variants, 450 variants of uncertain significance and 415 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Li-Fraumeni syndrome
TP53: Cellular tumor antigen p53
It coordinates transcriptional responses to DNA damage and other cellular stresses, promoting cell-cycle arrest, senescence, DNA repair, or apoptosis when appropriate. Loss of this tumor-suppressive control is one of the most common events in cancer, while germline pathogenic variants cause Li-Fraumeni syndrome.
188 ClinVar pathogenic / likely pathogenic and 857 uncertain variants in TP53 have source records linked to Li-Fraumeni syndrome. Association strength is not clinical gene validity.
CHEK2: Serine/threonine-protein kinase Chk2
It propagates DNA-damage checkpoint signals to proteins controlling cell-cycle arrest, repair, and apoptosis. Germline loss-of-function variants confer moderate cancer susceptibility, especially for breast cancer, while risk estimates depend on the specific allele and family context.
0 ClinVar pathogenic / likely pathogenic and 7 uncertain variants in CHEK2 have source records linked to Li-Fraumeni syndrome. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): CDKN2A.
Where Li-Fraumeni syndrome variants cluster
- TP53 DNA binding (positions 102–292): 158 of 168 ClinVar pathogenic / likely pathogenic variants, 1.9× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Li-Fraumeni syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| TP53 A138V | 138 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R158L | 158 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 Y163C | 163 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 V173M | 173 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R175H | 175 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R175G | 175 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 H179Q | 179 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R181C | 181 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 H193P | 193 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 L194R | 194 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 H214R | 214 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 Y220C | 220 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 M237I | 237 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 C238G | 238 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 G245S | 245 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R248W | 248 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R248Q | 248 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 I254T | 254 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 I254N | 254 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R273H | 273 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R280S | 280 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R110P | 110 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 L111Q | 111 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 L111R | 111 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 S127P | 127 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 S127T | 127 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 S127C | 127 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 C135G | 135 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 A138P | 138 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 V143A | 143 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 Y163H | 163 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R175L | 175 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 H214L | 214 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R248L | 248 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 V272M | 272 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R337C | 337 | Oligomerization | Pathogenic / likely pathogenic (★★★) |
| TP53 L344R | 344 | Nuclear export signal | Pathogenic / likely pathogenic (★★★) |
| TP53 L344P | 344 | Nuclear export signal | Pathogenic / likely pathogenic (★★★) |
| TP53 P151L | 151 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 P152L | 152 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 K164E | 164 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 H178D | 178 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 P190L | 190 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R337P | 337 | Oligomerization | Pathogenic / likely pathogenic (★★★) |
| TP53 R337L | 337 | Oligomerization | Pathogenic / likely pathogenic (★★★) |
| TP53 R110G | 110 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 K132N | 132 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 E180K | 180 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 V197M | 197 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 C277G | 277 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R283P | 283 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R337S | 337 | Oligomerization | Pathogenic / likely pathogenic (★★★) |
| TP53 R337G | 337 | Oligomerization | Pathogenic / likely pathogenic (★★★) |
| TP53 R342P | 342 | Nuclear export signal | Pathogenic / likely pathogenic (★★★) |
| TP53 S106R | 106 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 A347D | 347 | Nuclear export signal | Pathogenic / likely pathogenic (★★★) |
| TP53 R110L | 110 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 L111P | 111 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 S127Y | 127 | DNA binding | Pathogenic / likely pathogenic (★★★) |
| TP53 R158P | 158 | DNA binding | Pathogenic / likely pathogenic (★★★) |
Showing 60 of 188.
Uncertain variants prioritized for review in Li-Fraumeni syndrome
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| TP53 T125S | 125 | DNA binding | Conflicting reports (★) | +6: 7 other pathogenic changes within 3 positions; T125K at the same position is pathogenic; REVEL 0.963 |
| TP53 C275S | 275 | DNA binding | Conflicting reports (★) | +6: 11 other pathogenic changes within 3 positions; C275F at the same position is pathogenic; REVEL 0.982 |
| TP53 P278R | 278 | DNA binding | Conflicting reports (★) | +6: 13 other pathogenic changes within 3 positions; P278T at the same position is pathogenic; REVEL 0.951 |
| TP53 C242F | 242 | DNA binding | Conflicting reports (★) | +6: 15 other pathogenic changes within 3 positions; C242W at the same position is pathogenic; REVEL 0.977 |
| TP53 T125M | 125 | DNA binding | Conflicting reports (★) | +6: 7 other pathogenic changes within 3 positions; T125K at the same position is pathogenic; REVEL 0.925 |
| TP53 C277F | 277 | DNA binding | Conflicting reports (★) | +6: 8 other pathogenic changes within 3 positions; C277G at the same position is pathogenic; REVEL 0.932 |
| TP53 Y126C | 126 | DNA binding | Conflicting reports (★) | +6: 7 other pathogenic changes within 3 positions; Y126D at the same position is pathogenic; REVEL 0.981 |
| TP53 C135Y | 135 | DNA binding | Conflicting reports (★) | +6: 8 other pathogenic changes within 3 positions; C135R at the same position is pathogenic; REVEL 0.955 |
| TP53 K132E | 132 | DNA binding | Conflicting reports (★) | +6: 7 other pathogenic changes within 3 positions; K132N at the same position is pathogenic; REVEL 0.968 |
| TP53 Y126N | 126 | DNA binding | Conflicting reports (★) | +6: 7 other pathogenic changes within 3 positions; Y126D at the same position is pathogenic; REVEL 0.965 |
| TP53 A161D | 161 | DNA binding | Conflicting reports (★) | +6: 8 other pathogenic changes within 3 positions; A161T at the same position is pathogenic; REVEL 0.908 |
| TP53 C275G | 275 | DNA binding | Conflicting reports (★) | +6: 11 other pathogenic changes within 3 positions; C275F at the same position is pathogenic; REVEL 0.957 |
| TP53 E258G | 258 | DNA binding | Conflicting reports (★) | +6: E258K at the same position is pathogenic; REVEL 0.952 |
| TP53 P177S | 177 | DNA binding | Conflicting reports (★) | +6: 10 other pathogenic changes within 3 positions; P177R at the same position is pathogenic; REVEL 0.877 |
| TP53 R249G | 249 | DNA binding | Conflicting reports (★) | +6: 12 other pathogenic changes within 3 positions; R249S at the same position is pathogenic; REVEL 0.888 |
| TP53 C176R | 176 | DNA binding | Conflicting reports (★) | +6: 12 other pathogenic changes within 3 positions; C176F at the same position is pathogenic; REVEL 0.940 |
| TP53 H179N | 179 | DNA binding | Conflicting reports (★) | +6: 8 other pathogenic changes within 3 positions; H179R at the same position is pathogenic; REVEL 0.902 |
| TP53 N239T | 239 | DNA binding | Conflicting reports (★) | +6: 18 other pathogenic changes within 3 positions; N239S at the same position is pathogenic; REVEL 0.935 |
| TP53 H178P | 178 | DNA binding | Conflicting reports (★) | +6: 11 other pathogenic changes within 3 positions; H178D at the same position is pathogenic; REVEL 0.918 |
| TP53 E286G | 286 | DNA binding | Conflicting reports (★) | +6: 5 other pathogenic changes within 3 positions; E286K at the same position is pathogenic; REVEL 0.913 |
| TP53 P177L | 177 | DNA binding | Conflicting reports (★) | +6: 10 other pathogenic changes within 3 positions; P177R at the same position is pathogenic; REVEL 0.865 |
| TP53 S240R | 240 | DNA binding | Conflicting reports (★) | +6: 16 other pathogenic changes within 3 positions; S240G at the same position is pathogenic; REVEL 0.908 |
| TP53 M246R | 246 | DNA binding | Conflicting reports (★) | +6: 16 other pathogenic changes within 3 positions; M246K at the same position is pathogenic; REVEL 0.959 |
| TP53 G105D | 105 | DNA binding | Conflicting reports (★) | +6: 3 other pathogenic changes within 3 positions; G105R at the same position is pathogenic; REVEL 0.884 |
| TP53 P190R | 190 | DNA binding | Conflicting reports (★) | +6: 4 other pathogenic changes within 3 positions; P190L at the same position is pathogenic; REVEL 0.846 |
| TP53 Y220D | 220 | DNA binding | Conflicting reports (★) | +6: 4 other pathogenic changes within 3 positions; Y220C at the same position is pathogenic; REVEL 0.934 |
| TP53 C242G | 242 | DNA binding | Conflicting reports (★) | +6: 15 other pathogenic changes within 3 positions; C242W at the same position is pathogenic; REVEL 0.963 |
| TP53 F109V | 109 | DNA binding | Conflicting reports (★) | +6: 11 other pathogenic changes within 3 positions; F109I at the same position is pathogenic; REVEL 0.875 |
| TP53 R196G | 196 | DNA binding | Conflicting reports (★) | +6: 8 other pathogenic changes within 3 positions; R196P at the same position is pathogenic; REVEL 0.897 |
| TP53 H193L | 193 | DNA binding | Conflicting reports (★) | +6: 8 other pathogenic changes within 3 positions; H193N at the same position is pathogenic; REVEL 0.864 |
| TP53 M237V | 237 | DNA binding | Conflicting reports (★) | +6: 15 other pathogenic changes within 3 positions; M237K at the same position is pathogenic; REVEL 0.937 |
| TP53 A159P | 159 | DNA binding | Conflicting reports (★) | +6: 7 other pathogenic changes within 3 positions; A159D at the same position is pathogenic; REVEL 0.815 |
| TP53 F270L | 270 | DNA binding | Conflicting reports (★) | +6: 8 other pathogenic changes within 3 positions; F270S at the same position is pathogenic; REVEL 0.827 |
| TP53 G244R | 244 | DNA binding | Uncertain (★) | +6: 17 other pathogenic changes within 3 positions; G244A at the same position is pathogenic; REVEL 0.942 |
| TP53 R196Q | 196 | DNA binding | Uncertain (★★★) | +6: 8 other pathogenic changes within 3 positions; R196P at the same position is pathogenic; REVEL 0.888 |
| TP53 G105A | 105 | DNA binding | Uncertain (★) | +6: 3 other pathogenic changes within 3 positions; G105R at the same position is pathogenic; REVEL 0.905 |
| TP53 C277R | 277 | DNA binding | Uncertain (★★★) | +6: 8 other pathogenic changes within 3 positions; C277G at the same position is pathogenic; REVEL 0.889 |
| TP53 P151T | 151 | DNA binding | Uncertain (★★) | +6: 5 other pathogenic changes within 3 positions; P151S at the same position is pathogenic; REVEL 0.911 |
| TP53 H214P | 214 | DNA binding | Uncertain (★★) | +6: 4 other pathogenic changes within 3 positions; H214L at the same position is pathogenic; REVEL 0.932 |
| TP53 P177H | 177 | DNA binding | Uncertain (★★) | +6: 10 other pathogenic changes within 3 positions; P177R at the same position is pathogenic; REVEL 0.844 |
Which prediction tools work for Li-Fraumeni syndrome
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 97 out of 100
- MutPred: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 95 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 95 out of 100
- MetaLR: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaGenome (regulatory): 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- REVEL: 91 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 90 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- EVE: 90 out of 100
- SIFT: 86 out of 100
- CADD: 84 out of 100
- phyloP: 81 out of 100
- MetaSVM: 65 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SpliceAI: 57 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- DMS / MaveDB: 57 out of 100
- AlphaGenome (splicing): 57 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 50 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Adrenocortical carcinoma, hereditary also has ClinVar records linked to TP53 variants; they fall in the same places as the Li-Fraumeni syndrome variants (23 pathogenic / likely pathogenic).
- Acute myeloid leukemia also has ClinVar records linked to TP53 variants; they fall in the same places as the Li-Fraumeni syndrome variants (6 pathogenic / likely pathogenic).
- Hereditary breast ovarian cancer syndrome also has ClinVar records linked to TP53 variants; they fall in the same places as the Li-Fraumeni syndrome variants (6 pathogenic / likely pathogenic).
- Hereditary breast cancer also has ClinVar records linked to TP53 variants; they fall in the same places as the Li-Fraumeni syndrome variants (5 pathogenic / likely pathogenic).
- Glioma susceptibility also has ClinVar records linked to TP53 variants; they fall in the same places as the Li-Fraumeni syndrome variants (5 pathogenic / likely pathogenic).
Diseases related to Li-Fraumeni syndrome
- Hereditary breast cancer, also linked to CHEK2 and TP53
- Hereditary breast ovarian cancer syndrome, also linked to CHEK2 and TP53
- Colorectal cancer, also linked to CHEK2 and TP53
- Gastric cancer, also linked to CHEK2 and TP53
- Breast and/or ovarian cancer, also linked to CHEK2 and TP53
- Bone osteosarcoma, also linked to CHEK2 and TP53
- Prostate cancer, hereditary, also linked to CHEK2 and TP53
- Lynch syndrome, also linked to CHEK2
- Acute myeloid leukemia, also linked to TP53
- Adrenocortical carcinoma, hereditary, also linked to TP53
- Urinary bladder cancer, also linked to TP53
- Glioma susceptibility, also linked to TP53
Frequently asked questions
Which genes have records linked to Li-Fraumeni syndrome?
This view contains 2 analyzed proteins: TP53, CHEK2. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 188 pathogenic or likely pathogenic variants, 450 variants of uncertain significance and 415 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 50 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 1,147 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center